TITLE:
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

CONDITION:
Carcinoma, Renal Cell

INTERVENTION:
Sunitinib

SUMMARY:

      The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe
      in patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab
      (Avastin) -based treatment.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologically proven renal cell carcinoma of clear cell histology with metastases

          -  Evidence of measurable disease

          -  Radiographic evidence of disease progression during or within 3 months of completion
             of bevacizumab-based treatment

          -  Prior radical or partial nephrectomy

        Exclusion Criteria:

          -  Prior treatment with any other anti-angiogenic therapy other than bevacizumab

          -  Prior systemic treatment for RCC > 2 regimens

          -  History of or known brain metastases

          -  Serious acute or chronic illness or recent history of significant cardiac abnormality
      
